DaVita Inc. DVA is scheduled to report second-quarter 2025 results on Aug. 5, after the closing bell. In the last reported quarter, the company’s earnings per share (EPS) of $2.00 beat the Zacks ...

I bought Unicycive Therapeutics, Inc. (NASDAQ:UNCY) stock following the recent dip after the FDA issued a complete response letter, CRL for its New Drug Application, NDA for Oxylanthanum Carbonate, ...

Online survey findings showed significant challenges with compliance to phosphate binder therapy. Among 200 dialysis patients, 37% were non-compliant with their phosphate binders compared with 12% to ...

Please provide your email address to receive an email when new articles are posted on . Of survey respondents, 47% said large number and large size of pills were among top phosphate binder adherence ...

– Patient-reported outcomes from Phase 2 trial of oxylanthanum carbonate (OLC) demonstrate high patient satisfaction with OLC compared to their prior phosphate lowering therapy – – Findings from a ...

Secondary hyperparathyroidism is a complex endocrine condition characterized by excess circulating parathyroid hormone (PTH) resulting from an underlying condition, most commonly chronic kidney ...

LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ...

Taking phosphate binders may lower the risk of osteoporotic fractures in patients initiating dialysis. Oral phosphate binders may decrease the risk for osteoporotic fracture in patients starting ...

Please provide your email address to receive an email when new articles are posted on . Niacinamide was well-tolerated and did not increase the risk of thrombocytopenia. The treatment significantly ...

ISTANBUL, Turkey — The investigational drug PA21 controls hyperphosphatemia over the long term and has a lower pill burden than sevelamer carbonate, according to a phase 3 study. The cardiovascular ...

NEW YORK, Nov 30 (Reuters) - An experimental drug being developed by Keryx Biopharmaceuticals Inc to lower abnormally high levels of phosphate in the blood of patients with advanced kidney disease ...